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Five Spain9V-3 Streptococcus pneumoniae were isolated from a patient with bronchiectasis 
who had received long-term ciprofloxacin therapy: one ciprofloxacin-susceptible strain 
was isolated before treatment and four ciprofloxacin-resistant strains were isolated during 
treatment. Resistant strains derived from the susceptible either by parC mutation (low-
level resistance) or by parC plus gyrA mutation (high-level resistance). This study shows 
that ciprofloxacin therapy in a patient colonized with susceptible S. pneumoniae may 







Streptococcus pneumoniae remains a major etiological agent of community-acquired 
pneumonia, meningitis and acute otitis media. The emergence of resistance to antibiotics 
commonly used for the treatment of pneumococcal infections (13, 23) has highlighted the 
importance of the new fluoroquinolones that have been recommended for the treatment of 
respiratory tract infections (5). Although the prevalence of ciprofloxacin (Cip) resistance in S. 
pneumoniae is still low in Spain (3-7%) (1, 16, 27) and Canada (2%) (7), prior 
fluoroquinolone administration is a risk factor for resistant strains selection, as observed for 
infections caused by ciprofloxacin-resistant (CipR) (28) and levofloxacin-resistant (8, 34) S. 
pneumoniae. Likewise, resistance has been reported in blood isolates of viridans streptococci 
from neutropenic cancer patients who received fluoroquinolone prophylaxis (11, 35). 
The targets of the fluoroquinolones are DNA gyrase (gyrase, GyrA2GyrB2) and DNA 
topoisomerase IV (topo IV, ParC2ParE2) enzymes (9). The pneumococcal parC and parE 
genes are homologous to gyrA and gyrB, respectively (3, 19, 26). Biochemical studies have 
established that Cip inhibits preferentially the pneumococcal topo IV that gyrase enzymes (10, 
18, 24). Genetic studies have identified fluoroquinolone-resistance mutations in a discrete 
region of ParC, ParE, and GyrA termed the quinolone resistance-determining region (QRDR). 
Low-level (LL) CipR strains had mutations altering the QRDRs of one of the two subunits of 
topo IV:  S79 or D83 of ParC (12, 15, 19, 26, 32), D435 of ParE (29). High-level (HL) CipR 
strains had changes affecting both QRDRs of ParC and GyrA (S81, E85)(12, 15, 19, 26, 32) or 
ParE and GyrA (29). Direct biological evidence showing that those mutations are involved in 
resistance has been obtained by transformation experiments. Single parC mutations confer 
low-level (LL) Cip-resistance (14, 19, 32), and, once the cells have acquired this LL-CipR 
phenotype, it is possible to transform to a higher level of resistance using DNA containing the 





We describe herein the in vivo emergence of fluoroquinolone resistance in S. 
pneumoniae strains isolated from a patient that received multiple courses of Cip therapy for 
the treatment of a persistent Pseudomonas aeruginosa-infected bronchiectasis.  
 Patient history. A 64-year-old man was first seen in September-1996 with a longstanding 
history of chronic cough productive of purulent sputum. In his first clinical evaluation, a high-
resolution thoracic scanner demonstrated the presence of bilateral bronchiectasis, and a 
ciprofloxacin-sensitive (CipS) S. pneumoniae (3983) was isolated from the sputum. In April-
1997 he was first admitted to the hospital with a severe hypercapnic respiratory failure, and a 
CipS P. aeruginosa was isolated. Subsequently the patient received Cip (500 mg/ 12 h for 10 
days) for the exacerbations. In October-1997, a HL-CipR S. pneumoniae (4371) was isolated. 
The patient remained under control and free of exacerbations until March-1998, when a CipS 
S. pneumoniae (4579) was isolated. In September 1998, due to the isolation of a CipS 
Haemophilus influenzae and CipS Moraxella catharralis, the patient was reintroduced into 
Cip, and one month later a LL-CipR S. pneumoniae (4837) was isolated. In December-1998 
the patient had a hypercapnic respiratory failure and a HL-CipR S. pneumoniae (4866) and a 
CipS P. aeruginosa were isolated. In May-1999 he was readmitted to the hospital with a new 
infectious episode, a CipS S. pneumoniae (5181) and a CipS P. aeruginosa strain were isolated 
from sputum. From September-1999 to April-2000, the patient was treated regularly with Cip. 
On the visit at the Respiratory out-patient clinic (April-2000) the sputum yielded a CipR P. 
aeruginosa and a HL-CipR S. pneumoniae (5558). The patient died two weeks later due to an 
irreversible hypercapnic respiratory failure.   
 Characterization of S. pneumoniae isolates. The antibiotic resistance patterns of the 
strains, serotypes, MICs of selected fluoroquinolones (determined as previously described, 20) 
and QRDRs mutations are shown in Table 1. PCR products containing gyrA, gyrB, parC, and 





purified and sequenced on both strands. The HL-CipR (MIC  64 g/ml) strains showed cross-
resistance to other fluoroquinolones. Given the fluoroquinolone MICs for the LL-CipR 4837 
strain, this strain could be considered as susceptible according to the NCCLS breakpoint 
criteria (21). However this strain has mutations that would favor the appearance of HL-CipR 
strains and maybe those breakpoints should be revised in accordance. The LL-CipR strain 4837 
(MIC of 8 g/ml) had a parC mutation and the HL-CipR strains had parC plus gyrA mutations. 
Strains 3983, 4371 and 4837 share the same serotype (9V) and PFGE patterns 
(determined as described previously, 31), belonging to the Spain9V-3 clone (17). The two last 
9V serotype HL-CipR isolates (4866 and 5558) share an identical PFGE pattern that differs 
from that of the CipS 3983 and ATCC 700671 strains by three-band difference and are 
considered to be Spain9V-3 subtypes (33). Despite those PFGE pattern differences that could 
be a consequence of genome rearrangements that are common among S. pneumoniae (6), all 
Spain9V-3 strains showed identical polymorphisms on their QRDRs with respect to the 
sequence of the R6 strain: K137N change in ParC, I460V change in ParE, and a change in the 
Y74 codon of GyrA (TAT instead TAC) (Table 1). A genealogy of the strains was derived. 
The HL-CipR strain 4371 could derive from the CipS 3983 strain by acquisition of two 
changes: ParC S79Y and GyrA S81F. Although the LL-CipR strain from which strain 4371 
(October, 1997) has been derived has not been identified in this work, because sputum 
cultures were not performed between April-September 1997, that strain could be present in 
the respiratory tract of the patient during this period. Likewise, the LL-CipR 4837 strain could 
also derive from the CipS 3983 strain by acquisition of a S79F ParC change. The two last HL-
CipR isolates (strain 4866 and 16 months later, strain 5558) showed S79F ParC and S91F 
GyrA changes.  
The analysis of the S. pneumoniae strains sequentially isolated from this patient clearly 





secondary (gyrase) targets. Initially, the patient was infected-colonized by a CipS Spain9V-3 
strain (3983) and it was undergoing serial mutagenesis when he was receiving Cip therapy, 
yielding deferent degrees of Cip resistance (Fig. 1). This in vivo acquisition of resistance is 
consistent with genetic transformation experiments (15, 19) and with generation of CipR 
mutants (25) under laboratory conditions. The emergence of CipR S. pneumoniae occurred 
concurrently with Cip treatments and could be favored for the low serum concentrations 
yielded with this compound (1.5 – 3 g/ml), which is close to the MIC value (0.5 – 1 g/ml) 
for CipS strains. On the other hand two CipS strains (4579 and 5181), with different serotypes, 
PFGE types and gene polymorphisms appeared after periods without treatment, showing that 
without antibiotic pressure there was no selection of resistant mutants. 
 In our patient, previous chronic use of fluoroquinolones for a persistent bronchial 
infection was a risk factor in the development of antibiotic resistance, not only in the 
microorganisms considered causative of infectious exacerbations, such as P. aeruginosa, but 
also for those colonizing or co-infecting bronchiectasis. Results from our group demonstrated 
that prior fluoroquinolone use, purulent bronchitis and prior hospitalization, are risk factors 
for developing respiratory tract infections caused by CipR pneumococci (J. Liñares, F. Tubau, 
R. Pallarés, M. J. Ferrándiz, M. A. Domínguez, F. Manresa, A. G. de la Campa, and R. 
Martín. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 2106, 2000)  
Since infectious episodes are frequent and recurrent in chronic obstructive pulmonary 
disease (COPD) and bronchiectasis, antibiotics are generally prescribed in an empirical way, 
without bacteriological studies. Should the clinician reuse a fluoroquinolone in a patient with 
bronchiectasis once it has already been used? According to our own experience, and previous 
published data (8), a high risk of fluoroquinolone resistance development of S. pneumoniae in 
patients with recent fluoroquinolone therapy may exist, and it must be considered before the 





may develop cross-resistance to levofloxacin and other newer fluoroquinolones. Thus the 
empiric and systematic use of levafloxacin in the treatment of exacerbations of COPD or 
bronchiectasis has to be questioned, and a modification of the ATS (2) and IDSA (4) 
guidelines could be necessary.  
 Today, restriction of the use of fluoroquinolones and performance of susceptibility 
studies for monitoring the prevalence of fluoroquinolone-resistant pneumococci is 
recommended. It is important to keep in mind that most patients infected with invasive 
multiresistant pneumococci may still be treated with an appropriate betalactam such as 
amoxycillin or ceftriaxone (22, 23). 
 
We thank Dr A. Fenoll from the Spanish Pneumococcus Reference Laboratory (Centro 
Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda Madrid) for checking 
serotypes. To Dr. M. A. Dominguez for performing the PFGE analysis and critical reading of 
the manuscript. This work was supported by grants 00/0258 and 01/1267 from Fondo de 




1. Alou, L., M. Ramirez, C. García-Rey, J. Prieto, and H. de Lencastre. 2001. 
Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in 
Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. 
Antimicrob. Agents Chemother. 45:2955-2957. 
2. American Thoracic Society. 2001. Guidelines for the management of adults with 
community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial 





3. Balas, D., E. Fernández-Moreira, and A. G. de la Campa. 1998. Molecular 
characterization of the gene encoding the DNA gyrase A subunit of Streptococcus 
pneumoniae. J. Bacteriol. 180:2854-2861. 
4. Barlett, J. G., S. F. Dowell, L. A. Mandell, T. L. File Jr, D. L. Musher, and M. J. 
Fine. 2000. Guidelines from IDSA: practice guidelines for the management of adults 
with community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382. 
5. Bartlett, J. G., R. F. Breiman, L. Mandell, and T. M. File. 1998. Community-
acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-
838. 
6. Claverys, J.-P., M. Prudhomme, I. Martier-Barrière, and B. Martin. 2000. 
Adaptation to the environment: Streptococcus pneumoniae, a paradigm for 
recombination-mediated genetic plasticity? Mol. Microbiol. 35:251-259. 
7. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased 
susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. 
Med. 341:233-239. 
8. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. S. de Azevedo, P. 
Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and faillure of 
treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750 
9. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. 
Microbiol. Mol. Biol. Rev. 61:377 -392. 
10. Fernández-Moreira, E., D. Balas, I. González, and A. G. de la Campa. 2000. 
Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA 
topoisomerase than DNA gyrase native proteins. Microb. Drug Res. 6:259-267. 
11. González, I., M. Georgiou, F. Alcaide, D. Balas, J. Liñares, and A. G. de la 





genes of clinical isolates of viridans group streptococci. Antimicrob. Agents 
Chemother. 42:2792-2798. 
12. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. 
Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin 
(cp-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus 
pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697. 
13. Hoffman, J., M. S. Cetron, M. M. Farley, W. S. Baughman, R. R. Facklam, J. A. 
Elliot, K. A. Deaver, and R. F. Breiman. 1995. The prevalence of drug-resistant 
Streptococcus pneumoniae in Atlanta. N. Engl. J. Med. 333:481-486. 
14. Janoir, C., I. Podglajen, M. D. Kitzis, C. Poyart, and L. Gutmann. 1999. In vitro 
exchange of fluoroquinolone resistance determinants between Streptococcus 
pneumoniae and viridans streptococci and genomic organization of the parE-parC 
region in S. mitis. J. Infect. Dis. 180:555-558. 
15. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-
level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in 
parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764. 
16. Liñares, J., A. G. de la Campa, and R. Pallarés. 1999. Fluoroquinolone resistance in 
Streptococcus pneumoniae. N. Engl. J. Med. 341:1546-1548. 
17. McGee, L., L. McDougal, J. Zhou, B. G. Spratt, F. C. Tenover, R. George, R. 
Hakenbeck, W. Hryniewicz, J. C. Lefevre, A. Tomasz, and K. P. Klugman. 2001. 
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae 






18. Morrissey, I., and J. George. 1999. Activities of fluoroquinolones against 
Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. 
Antimicrob. Agents Chemother. 43:2579-2585. 
19. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of 
Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with 
DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents  
Chemother. 40:2252-2257. 
20. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution 
antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Publication 
M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa. 
21. National Committee for Clinical Laboratory Standards. 2002. Performance 
standards for antimicrobial susceptibility testing; twelfth informational supplement. 
Publication M100-S12. National Committee for Clinical Laboratory Standards, 
Wayne, Pa. 
22. Pallarés, R., O. Capdevila, J. Liñares, I. Grau, H. Onaga, F. Tubau, M. H. 
Schulze, P. Hohl, and F. Gudiol. 2002. The effect of cephalosporin resistance on 
mortality in adult patients with nonmeningeal systemic pneumococcal infections. 
Amm. J. Med. 113:120-126. 
23. Pallarés, R., J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. 
Martín, and F. Gudiol. 1995. Resistance to penicillin and cephalosporins and 
mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 
333:474-480. 
24. Pan, X. S., and L. M. Fisher. 1999. Streptococcus pneumoniae DNA gyrase and 
topoisomerase IV: overexpression, purification, and differential inhibition by 





25. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of 
topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus 
pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326. 
26. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and 
parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in 
fluoroquinolone resistance. J. Bacteriol. 178:4060-4069. 
27. Pérez-Trallero, E., C. Fernández-Mazarrasa, C. García-Ret, E. Bouza, L. 
Aguilar, J. García de Lomas, F. Baquero, and T. S. S. G. f. R. Pathogens. 2001. 
Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 
Streptococcus pyogenes isolates and their ecological relationships: results of 1-year 
(1998-1999) multicenter study in Spain. Antimicrob Agents Chemother. 45:3334-
3340. 
28. Pérez-Trallero, E., J. M. García-Arenzana, J. A. Jiménez, and A. Peris. 1990. 
Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal 
 pneumonia treated with ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 9:905-906. 
29. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in 
the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. 
Antimicrob. Agents. Chemother. 41:166-167. 
30. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory 
manual, 2nd ed. Cold Spring Harbor laboratory Press, Cold Spring harbor, N. Y. 
31. Soares, S., K. G. Kristisson, J. M. Musser, and A. Tomasz. 1993. Evidence for the 
introduction of a multirresistant clone of serotype 6B Streptococcus pneumoniae from 
Spain to Iceland in the late 1980s. J. Infect. Dis. 168:158-163. 
32. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of 





Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents 
Chemother. 40:2505-2510. 
33. Tenover, F. C., R. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. 
Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction 
patterns produced by pulse-field gel electrophoresis: criteria for bacterial strain typing. 
J. Clin. Microbiol. 33:2233-2239. 
34. Urban, C., N. Rahman, X. Zhao, N. Mariano, S. A. Segal-maurer, K. Drlica, and 
J. J. Rahal. 2001. Fluoroquinolone-resistant Streptococcus pneumoniae associated 
with levofloxacin therapy. J. Infect. Dis. 184:794-798. 
35. Venditti, M., P. Baiocchi, C. Barandimarte, P. Serra, G. Gentile, C. Girmenia, 
and P. Martino. 1989. Antimicrobial susceptibilities of Streptococcus species that 










FIG. 1. Time course of ciprofloxacin treatments and emergence of S. pneumoniae strains.  






TABLE 1. Susceptibilities to fluoroquinolones and mutations in the topoisomerases QRDR of S. pneumoniae clinical isolates a  
 
Strain Type PFGE a Resistance  
pattern b 
MIC (g/ml) of c: Mutation(s) in the QRDR of: d  
    CIP LVX GAT MXF ParC GyrAb ParEb 
R6 NT  S 0.5 0.5 0.25 0.12 None None None 
ATCC 49619 19F  PEN 1 1 0.25 0.12 None Y74 (TAT) None 
ATCC 700671 9V Spain9V -3 PENSXT 1 0.5 0.25 0.12 K137N Y74 (TAT) I460V 
3983 9V Spain9V -3 PENSXT 1 0.5 0.25 0.12 K137N Y74 (TAT) I460V 
4371 9V Spain9V -3 PENSXT 128 32 8 4 S79Y, K137N S81F, Y74 (TAT) I460V 
4579 10 B S 1 0.5 0.25 0.12 K137N   
4837 9V Spain9V -3 PENSXT 8 2 0.5 0.25 S79F, K137N  Y74 (TAT) I460V 
4866 9V Spain9V -3* PENSXT 64 16 4 4 S79F, K137N S81F, Y74 (TAT) I460V 
5181 NT D S 0.5 0.5 0.25 0.12 K137N   






a The asterisk indicates that those strains are Spain9V-3 clone subtypes.   
b S, susceptible to all antibiotics tested; PEN, resistant to penicillin (MICs of 2-4 g/ml, except for ATCC 49619 that was 0.25 g/ml); SXT; 
resistant to trimethropim-sulfamethoxazole (MICs of 4/76 g/ml); . 
c CIP, ciprofloxacin; LVX, levofloxacin; GAT, gatifloxacin; MXF, moxifloxacin. 
d Residue changes involved in fluoroquinolones resistance are underlined. Mutations (by reference to the R6 DNA sequence) were as follows: 
ParC, S79F (TCTTTT), K137N (AAGAAT); GyrA S81F (TCCTTC); ParE I460V (ATCGTC). The strains indicated harbored a silent 
mutation (TACTAT) at codon 74 of the gyrA sequence. No changes in the QRDR of GyrB were found.  , not determined. 
 
 
